Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Free Report) – Equities research analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Neuphoria Therapeutics Inc. – Common Stock in a note issued to investors on Tuesday, February 4th. HC Wainwright analyst J. Pantginis expects that the company will post earnings of ($1.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s FY2028 earnings at ($1.36) EPS.
Neuphoria Therapeutics Inc. – Common Stock Price Performance
Shares of NEUP stock opened at $5.15 on Wednesday. Neuphoria Therapeutics Inc. – Common Stock has a 1-year low of $2.12 and a 1-year high of $16.08.
Neuphoria Therapeutics Inc. – Common Stock Company Profile
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
See Also
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Must-Have ETFs Set to Dominate This Quarter
- Do ETFs Pay Dividends? What You Need to Know
- Seeking Stability? These 3 Stocks Offer Strong Potential
- Are Penny Stocks a Good Fit for Your Portfolio?
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
